Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis

  • Original Article
  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

Patients with rheumatoid arthritis (RA) suffer from a magnitude of excess cardiovascular risk. A paradoxical lipid pattern has been observed in rheumatoid arthritis patients where low levels of total cholesterol and low-density lipoprotein are associated with a higher risk of cardiovascular disease. This paper aims to break down the evidence explaining why patients with low to normal LDL, and total cholesterol have such excess cardiovascular risk. A component of the enhanced cardiovascular risk is systemic inflammation and the subsequent pro-atherogenic dyslipidemia patterns. Due to this “lipid paradox,” current risk algorithms and guidelines designed for the general population may underestimate cardiovascular risk in patients with rheumatoid arthritis. The purpose of this paper is to critically evaluate some of the discrepancies and layers of cardiovascular risk in RA patients, the role RA medication may have in mitigating or increasing cardiovascular risk, and the possible role of statin therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Meyer, P. W., Anderson, R., Ker, J. A., & Ally, M. T. (2018). Rheumatoid arthritis and risk of cardiovascular disease. Cardiovascular Journal of Africa, 29(5), 317–321.

    PubMed  Google Scholar 

  2. Liao, K. P., Playford, M. P., Frits, M., et al. (2015). The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. Journal of the American Heart Association, 4(2), e001588. Published 2015 Jan 30. https://doi.org/10.1161/JAHA.114.001588.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Bag-Ozbek, A., & Giles, J. T. (2015). Inflammation, adiposity, and atherogenic dyslipidemia in rheumatoid arthritis: is there a paradoxical relationship? Current Allergy and Asthma Reports, 15(2), 497.

    PubMed  Google Scholar 

  4. Siebert, S., Lyall, D. M., Mackay, D. F., et al. (2016). Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants. RMD Open, 2(1), e000267 Published 2016 Jun 14.

    PubMed  PubMed Central  Google Scholar 

  5. Sattar, N., McCarey, D. W., Capell, H., & McInnes, I. B. (2003). Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation., 108(24), 2957–2963.

    PubMed  Google Scholar 

  6. Van Halm, V. O., Peters, M. J. L., Voskyl, A. E., et al. (2009). Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE investigation. Annals of the Rheumatic Diseases, 68, 1396–1400.

    Google Scholar 

  7. Khalid, U., Egeberg, A., Ahlehoff, O., et al. (2018). Incident heart failure in patients with rheumatoid arthritis: a nationwide cohort study. Journal of the American Heart Association, 7(2), e007227.

    PubMed  PubMed Central  Google Scholar 

  8. Agca, R., Heslinga, S. C., Rollefstad, S., et al. (2017). EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases, 76(1), 17–28.

    CAS  PubMed  Google Scholar 

  9. Maradit-Kremers, H., Crowson, C. S., Nicola, P. J., Ballman, K. V., Roger, V. L., Jacobsen, S. J., & Gabriel, S. E. (2005). Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis and Rheumatism, 52(2), 402–411.

    PubMed  Google Scholar 

  10. Nicola, P. J., Maradit-Kremers, H., Roger, V. L., Jacobsen, S. J., Crowson, C. S., Ballman, K. V., & Gabriel, S. E. (2005). The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis and Rheumatism, 52(2), 412–420.

    PubMed  Google Scholar 

  11. Rawla, P. (2019). Cardiac and vascular complications in rheumatoid arthritis. Reumatologia., 57(1), 27–36. https://doi.org/10.5114/reum.2019.83236.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Khovidhunkit, W., Memon, R. A., Feingold, K. R., & Grunfeld, C. (2000). Infection and inflammation-induced proatherogenic changes of lipoproteins. The Journal of Infectious Diseases, 181(Suppl 3), S462–S472.

    CAS  PubMed  Google Scholar 

  13. Kim, J. Y., Lee, E. Y., Park, J. K., et al. (2016). Patients with rheumatoid arthritis show altered lipoprotein profiles with dysfunctional high-density lipoproteins that can exacerbate inflammatory and atherogenic process. PLoS One, 11(10), e0164564.

    PubMed  PubMed Central  Google Scholar 

  14. Ajeganova, S., Ehrnfelt, C., Alizadeh, R., et al. (2011). Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset--a prospective cohort study. Rheumatology (Oxford, England), 50(10), 1785–1793.

    CAS  Google Scholar 

  15. Emdin, C. A., Khera, A. V., Natarajan, P., et al. (2016). Phenotypic characterization of genetically lowered human lipoprotein(a) levels. Journal of the American College of Cardiology, 68(25), 2761–2772.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Tsimikas, S., Karwatowska-Prokopczuk, E., Gouni-Berthold, I., et al. (2020 Jan). Lipoprotein(a) reduction in persons with cardiovascular disease. The New England Journal of Medicine, 1.

  17. García-Gómez, C., Bianchi, M., de la Fuente, D., et al. (2014). Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: a qualitative relationship? World Journal of Orthopedics, 5(3), 304–311 Published 2014 Jul 18.

    PubMed  PubMed Central  Google Scholar 

  18. Singh, J. A., Saag, K. G., Bridges Jr., S. L., et al. (2015). American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research (Hoboken), 68(1), 1–25.

    Google Scholar 

  19. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3026]. J Am Coll Cardiol. 2014;63(25 Pt B):2935–2959.

  20. Grundy SM, Stone NJ, Nailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS APhA/ASPC/NLA/PCBA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Journal of the American College of Cardiology Nov 2018; DOI: https://doi.org/10.1016/j.jacc.2018.11.003.

  21. Crowson, C. S., Matteson, E. L., Roger, V. L., et al. (2012). Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis. The American Journal of Cardiology, 110(3), 420–424.

    PubMed  PubMed Central  Google Scholar 

  22. Arts, E. E., Popa, C., Den Broeder, A. A., et al. (2015). Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Annals of the Rheumatic Diseases, 74(4), 668–674.

    CAS  PubMed  Google Scholar 

  23. Ronda, N., Greco, D., Adorni, M. P., et al. (2015). Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. Arthritis & Rhematology, 67(5), 1155–1164.

    CAS  Google Scholar 

  24. Page, R. L., O'Bryant, C. L., Cheng, D., et al. (2016). Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation., 134, e32–e69.

    CAS  PubMed  Google Scholar 

  25. Naerr, G. W., Rein, P., Saely, C. H., & Drexel, H. (2016). Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascular Pharmacology, 81, 22–30.

    CAS  PubMed  Google Scholar 

  26. Roubille, C., Richer, V., Starnino, T., et al. (2015). The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Annals of the Rheumatic Diseases, 74(3), 480–489.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. The American Journal of Cardiology 2011;108(9):1362–1370.

  28. Moreira, D. M., Vieira, J. L., & Gottschall, C. A. (2009). The effects of METhotrexate therapy on the physical capacity of patients with ISchemic heart failure: a randomized double-blind, placebo-controlled trial (METIS trial). Journal of Cardiac Failure, 15(10), 828–834.

    CAS  PubMed  Google Scholar 

  29. Gong, K., Zhang, Z., Sun, X., et al. (2006). The nonspecific anti-inflammatory therapy with methotrexate for patients with chronic heart failure. American Heart Journal, 151(1), 62–68.

    CAS  PubMed  Google Scholar 

  30. Lauper, K., & Gabay, C. (2017). Cardiovascular risk in patients with rheumatoid arthritis. Seminars in Immunopathology, 39(4), 447–459.

    CAS  PubMed  Google Scholar 

  31. Shapiro, M., & Levy, Y. (2017). The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. Oncotarget, 9(5), 6615–6622 Published 2017 Dec 15.

    PubMed  PubMed Central  Google Scholar 

  32. Sharma, T. S., Wasko, M. C., Tang, X., et al. (2016). Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. Journal of the American Heart Association, 5(1), e002867 Published 2016 Jan 4.

    PubMed  PubMed Central  Google Scholar 

  33. Restrepo, J. F., Del Rincon, I., Molina, E., Battafarano, D. F., & Escalante, A. (2017). Use of hydroxychloroquine is associated with improved lipid profile in rheumatoid arthritis patients. Journal of Clinical Rheumatology, 23(3), 144–148.

    PubMed  PubMed Central  Google Scholar 

  34. Karimifar, M., Sepehrifar, M. S., Moussavi, H., et al. (2018). The effects of conventional drugs in the treatment of rheumatoid arthritis on the serum lipids. Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences, 23, 105.

    CAS  Google Scholar 

  35. Joyce, E., Fabre, A., & Mahon, N. (2013). Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. European Heart Journal Acute Cardiovascular Care, 2(1), 77–83.

    PubMed  PubMed Central  Google Scholar 

  36. MacMullan, P. A., Madigan, A. M., Paul, N., et al. (2016). Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis. Clinical Rheumatology, 35(2), 447–455.

    PubMed  Google Scholar 

  37. Cildag, S., & Senturk, T. (2017). Sulfasalazine-related hypersensitivity reactions in patients with rheumatic diseases. Journal of Clinical Rheumatology, 23(2), 77–79.

    PubMed  Google Scholar 

  38. Nurmohamed, M. T., van Halm, V. P., & Dijkmans, B. A. (2002). Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. Drugs., 62(11), 1599–1609.

    CAS  PubMed  Google Scholar 

  39. Bergström, U., Jovinge, S., Persson, J., et al. (2018). Effects of treatment with adalimumab on blood lipid levels and atherosclerosis in patients with rheumatoid arthritis. Current Therapeutic Research, Clinical and Experimental, 89, 1–6.

    PubMed  PubMed Central  Google Scholar 

  40. Mann, D. L., McMurray, J. J., Packer, M., et al. (2004). Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation., 109(13), 1594–1602.

    CAS  PubMed  Google Scholar 

  41. Chung, E. S., Packer, M., Lo, K. H., et al. (2003). Randomized, double-blind, placebo- controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation., 107(25), 3133–3140.

    CAS  PubMed  Google Scholar 

  42. Van Taunay, J. S., Albelda, M. T., Frias, J. C., et al. (2018). Biologics and cardiovascular disease. Journal of Cardiovascular Pharmacology, 72(2), 77–85.

    PubMed  Google Scholar 

  43. Low, A. S. L., Symmons, D. P. M., Lunt, M., et al. (2017). Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 76, 654–660.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. Monaco, C., Nanchahal, J., Taylor, P., & Feldmann, M. (2015). Anti-TNF therapy: past, present and future. International Immunology, 27(1), 55–62.

    CAS  PubMed  Google Scholar 

  45. Nurmohamed, M., Choy, E., Lula, S., Kola, B., DeMasi, R., & Accossato, P. (2018). The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Safety, 41(5), 473–488.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Gabay, C., McInnes, I. B., Kavanaugh, A., et al. (2016). Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 75(10), 1806–1812.

    PubMed  Google Scholar 

  47. Keystone, E. C., Combe, B., Smolen, J., et al. (2012). Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. Rheumatology (Oxford, England), 51(9), 1628–1638.

    CAS  Google Scholar 

  48. Deodhar, A., Bitman, B., Yang, Y., et al. (2016). The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis. Clinical Rheumatology, 35(12), 3045–3052.

    PubMed  PubMed Central  Google Scholar 

  49. Kirkham, B. W., Wasko, M. C., Hsia, E. C., et al. (2014). Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Annals of the Rheumatic Diseases, 73(1), 161–169.

    CAS  PubMed  Google Scholar 

  50. O'Neill, F., Charakida, M., Topham, E., et al. (2017). Anti-inflammatory treatment improves high-density lipoprotein function in rheumatoid arthritis. Heart., 103(10), 766–773.

    CAS  PubMed  Google Scholar 

  51. Mathieu, S., Couderc, M., Glace, B., et al. (2013). Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics., 7, 259–264.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Hsue, P. Y., Scherzer, R., Grunfeld, C., et al. (2014). Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. Journal of the American Heart Association, 3(5), e001267 Published 2014 Oct 21.

    PubMed  PubMed Central  Google Scholar 

  53. García-Gómez, C., Martín-Martínez, M. A., Castañeda, S., et al. (2017). Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: results from the CARdiovascular in rheuMAtology study project. Journal of Clinical Lipidology, 11(3), 749–756.e3.

    PubMed  Google Scholar 

  54. Charles-Schoeman, C., Gonzalez-Gay, M. A., Kaplan, I., et al. (2016). Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist. Seminars in Arthritis and Rheumatism, 46(1), 71–80.

    CAS  PubMed  Google Scholar 

  55. McInnes, I. B., Thompson, L., Giles, J. T., et al. (2015). Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Annals of the Rheumatic Diseases, 74(4), 694–702.

    CAS  PubMed  Google Scholar 

  56. Jabbari, A., Dai, Z., Xing, L., et al. (2015). Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine, 2(4), 351–355.

    PubMed  PubMed Central  Google Scholar 

  57. Blume-Peytavi, U., & Vogt, A. (2015). Translational positioning of Janus kinase (JAK) inhibitors in alopecia areata. EBioMedicine, 2, 282–283.

    PubMed  PubMed Central  Google Scholar 

  58. Cheung, T. T., & McInnes, I. B. (2017). Future therapeutic targets in rheumatoid arthritis? Seminars in Immunopathology, 39(4), 487–500.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Strand, V., van Vollenhoven, R. F., Lee, E. B., et al. (2016). Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatology (Oxford, England), 55(6), 1031–1041.

    CAS  Google Scholar 

  60. Center for Drug Evaluation and Research. Safety trial finds risk of blood clots in the lungs. U.S. Food and Drug Administration.https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and. Published July 26, 2019.

  61. Liang, H., Danwada, R., Guo, D., et al. (2019). Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD Open, 5(2), e001013. Published 2019 Sep 23. https://doi.org/10.1136/rmdopen-2019-001013.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Taylor, P. C., Keystone, E. C., van der Heijde, D., et al. (2017). Baricitinib versus placebo or adalimumab in rheumatoid arthritis. The New England Journal of Medicine, 376(7), 652–662.

    CAS  PubMed  Google Scholar 

  63. Kremer, J. M., Genovese, M. C., Keystone, E., et al. (2017). Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis. Arthritis & Rhematology, 69(5), 943–952.

    CAS  Google Scholar 

  64. Xing, B., Yin, Y. F., Zhao, L. D., et al. (2015). Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis. Medicine (Baltimore), 94(8), e572.

    CAS  Google Scholar 

  65. Schoenfeld, S. R., Lu, L., Rai, S. K., et al. (2016). Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. Annals of the Rheumatic Diseases, 75(7), 1315–1320.

    CAS  PubMed  Google Scholar 

  66. Cobbaert, C., Jukema, J. W., Zwinderman, A. H., et al. (1997). Modulation of lipoprotein(a) atherogenicity by high density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression growth evaluation statin study (REGRESS) study group. Journal of the American College of Cardiology, 30(6), 1491–1499.

    CAS  PubMed  Google Scholar 

  67. McInnes, I. B., Kim, H. Y., Lee, S. H., Mandel, D., Song, Y. W., Connell, C. A., Luo, Z., Brosnan, M. J., Zuckerman, A., Zwillich, S. H., & Bradley, J. D. (2014). Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Annals of the Rheumatic Diseases, 73(1), 124–131.

    CAS  PubMed  Google Scholar 

  68. Abeles, A. M., & Pillinger, M. H. (2006). Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis and Rheumatism, 54(2), 393–407.

    CAS  PubMed  Google Scholar 

  69. Li, G. M., Zhao, J., Li, B., et al. (2018). The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials. Autoimmunity Reviews, 17(3), 215–225.

    CAS  PubMed  Google Scholar 

  70. Kitas GD, Nightingale P, Armitage J, et al. A Multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019.

  71. Huang CY, Lin TT, Yang YH, et al. Effect of statin therapy on the prevention of new-onset acute coronary syndrome in patients with rheumatoid arthritis.

Download references

Author information

Authors and Affiliations

  1. Rueckert-Hartman College for Health Professions, School of Pharmacy, Regis University, 3333 Regis Blvd H-28, Denver, CO, 80221, USA

    Juli Halacoglu & Leticia A. Shea

Authors
  1. Juli Halacoglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leticia A. Shea
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leticia A. Shea.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics Approval

Ethical approval was not required by the IRB as it is a review and no human subjects were studied by the authors of this manuscript.

Informed Consent

N/A

Trial Registration

N/A

Additional information

Editor-in-Chief Enrique Lara-Pezzi oversaw the review of this article

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Halacoglu, J., Shea, L.A. Cardiovascular Risk Assessment and Therapeutic Implications in Rheumatoid Arthritis. J. of Cardiovasc. Trans. Res. 13, 878–890 (2020). https://doi.org/10.1007/s12265-020-09964-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-020-09964-9

Keywords

Search

Navigation